Optimi Health Corp. (TSE:OPTI) has released an update.
Optimi Health Corp., a GMP psychedelics manufacturer, has secured a Certificate of Analysis for its 40mg and 60mg MDMA capsules, affirming the product meets GMP quality standards. The company completed GMP validation for these dosages, ensuring the capsules are uniform, stable, and comply with regulatory requirements. In addition, Optimi has announced the closing of the final tranche of its private placement, aiming to raise up to CAD$1,500,000 in total funding.
For further insights into TSE:OPTI stock, check out TipRanks’ Stock Analysis page.
